29.66

2.79% -0.85

Pre-market: 28.01 -1.65 -5.56%

Tg Therapeutics Inc (TGTX)

Overview News Price History Option Chain Financials Why TGTX Down? Discussions Forecast Stock Split

Tg Therapeutics Inc stock is traded at $29.66, with a volume of 2.37M. It is down -2.79% in the last 24 hours and down -4.94% over the past month. TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Previous Close:

$30.51

Open:

$30.29

24h Volume:

2.37M

Relative Volume:

1.31

Market Cap:

$4.71B

Revenue:

$264.79M

Net Income/Loss:

$-14.36M

P/E Ratio:

-269.64

EPS:

-0.11

Net Cash Flow:

$-28.11M

1W Performance:

+1.47%

1M Performance:

-4.94%

6M Performance:

+3.96%

1Y Performance:

+1.54%

1-Day Range:

$29.64

$30.72

1-Week Range:

$28.69

$31.08

52-Week Range:

$25.28

$46.48

Tg Therapeutics Inc Stock (TGTX) Company Profile

Name

Tg Therapeutics Inc

Sector

Healthcare (1108)

Industry

Biotechnology (621)

Phone

(212) 554-4484

Address

2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY

Employee

352

Twitter

@TGTherapeutics

Next Earnings Date

2025-03-03

Latest SEC Filings

TGTX's Discussions on Twitter

Compare TGTX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TGTX Tg Therapeutics Inc	29.66	4.84B	264.79M	-14.36M	-28.11M	-0.11
VRTX Vertex Pharmaceuticals Inc	483.05	123.82B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	784.28	81.64B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	816.95	52.00B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	327.36	44.14B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	352.23	40.83B	4.98B	69.60M	525.67M	0.5198

Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-06-25	Resumed	H.C. Wainwright	Buy
Jul-10-25	Resumed	Goldman	Neutral
Oct-29-24	Initiated	TD Cowen	Buy
Aug-02-23	Upgrade	Goldman	Sell → Neutral
Jun-26-23	Resumed	Jefferies	Buy
May-20-22	Initiated	BofA Securities	Underperform
Feb-23-22	Reiterated	B. Riley Securities	Buy
Nov-15-21	Downgrade	Goldman	Neutral → Sell
Apr-20-21	Initiated	Goldman	Neutral
Apr-19-21	Reiterated	H.C. Wainwright	Buy
Sep-01-20	Initiated	JP Morgan	Overweight
Aug-11-20	Reiterated	H.C. Wainwright	Buy
Jun-05-20	Initiated	Evercore ISI	Outperform
Jan-17-20	Reiterated	H.C. Wainwright	Buy
Nov-27-19	Resumed	B. Riley FBR	Buy
Feb-06-19	Resumed	Jefferies	Buy
Sep-25-18	Downgrade	Raymond James	Strong Buy → Outperform
Mar-09-18	Reiterated	B. Riley FBR, Inc.	Buy
Dec-01-17	Resumed	B. Riley FBR, Inc.	Buy
Nov-14-17	Resumed	H.C. Wainwright	Buy
Apr-25-17	Initiated	Jefferies	Buy
Mar-06-17	Reiterated	FBR & Co.	Outperform
Oct-06-16	Resumed	Brean Capital	Buy
May-27-16	Initiated	SunTrust	Buy
Dec-01-15	Initiated	FBR Capital	Outperform
Sep-09-15	Initiated	Raymond James	Strong Buy
Aug-12-15	Resumed	H.C. Wainwright	Buy
Jun-19-15	Reiterated	Brean Capital	Buy
Dec-11-14	Reiterated	ROTH Capital	Buy
Dec-10-14	Reiterated	ROTH Capital	Buy

View All

Tg Therapeutics Inc Stock (TGTX) Latest News

Feb 25, 2026

A Look at TG Therapeutics's Upcoming Earnings Report - Benzinga

Feb 25, 2026

TG Therapeutics faces earnings test as Briumvi growth accelerates - Investing.com India

Feb 25, 2026

TG Therapeutics (TGTX) Set to Announce Q4 Earnings with Positive Revisions - GuruFocus

Feb 25, 2026

FOMO Trade: Is TG Therapeutics Inc a top pick in the sectorWeekly Stock Summary & Precise Entry and Exit Recommendations - baoquankhu1.vn

Feb 25, 2026

Feb 24, 2026

Goldman Sachs raises TG Therapeutics, Inc. (TGTX) target to $39 on 2026 guidance - MSN

Feb 24, 2026

Feb 23, 2026

Aug Rallies: Is TG Therapeutics Inc undervalued by DCF analysisWeekly Investment Report & Expert Curated Trade Setup Alerts - baoquankhu1.vn

Feb 23, 2026